Multiplicities in cancer research: Ubiquitous and necessary evils

Journal of the National Cancer Institute

Volumn 104, Issue 15, 2012, Pages 1124-1132

  Berry, Donald ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER EPIDEMIOLOGY; CANCER RESEARCH; FALSE POSITIVE RESULT; HUMAN; PRIORITY JOURNAL; PUBLICATION; REVIEW; STATISTICAL ANALYSIS;

BAYES THEOREM; BIOMEDICAL RESEARCH; DISEASE-FREE SURVIVAL; EMPIRICAL RESEARCH; GENOME-WIDE ASSOCIATION STUDY; HUMANS; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; RESEARCH REPORT; TUMOR MARKERS, BIOLOGICAL;

EID: 84864955493     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs301     Document Type: Review

References (29)

1. Berry DA. The difficult and ubiquitous problems of multiplicities. Pharm Stat. 2007;6(3):155-160. (Pubitemid 47455255)
2. Gould SJ. Cordelia's dilemma. Nat Hist. 1993;102(2):10-18.
3. Purssell E, While A. P = nothing, or why we should not teach healthcare students about statistics. Nurse Educ Today. 2011;31(8):837-840.
4. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43-46. (Pubitemid 20255621)
5. Berry DA. Statistics: A Bayesian Perspective. Belmont, CA: Duxbury; 1996.
6. Lehrer J. The truth wears off. The New Yorker. Dec 13, 2010. http://www.newyorker.com/reporting/2010/12/13/101213fa-fact-lehrer.
7. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. doi:10.1371/journal.pmed.0020124. (Pubitemid 46179232)
8. Huang X, Biswas S, Estey EH, Berry DA. Building and validating a prognostic index for biomarker studies. Dis Markers. 2006;2(3-4):97-101.
9. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-2826. (Pubitemid 40051905)
10. Pe'er I, Yelensky R, Altshuler D, Daly MJ. Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. Genet Epidemiol. 2008;32(4):381-385. (Pubitemid 351656309)
11. Berry DA. Multiple comparisons, multiple tests, and data dredging: a Bayesian perspective (with discussion). In: Bernardo JM, et al., eds. Bayesian Statistics. Vol 3. Oxford, UK: Oxford University; 1988:79-94.
12. Berry DA, Hochberg Y. Bayesian perspectives on multiple comparisons. J Stat Plan Infer. 1999;82(1):215-227.
13. Gopalan R, Berry DA. Bayesian multiple comparisons using Dirichlet process priors. J Am Stat Assoc. 1998;93:1130-1139.
14. Berger JO, Berry DA. Statistical analysis and the illusion of objectivity. Am Sci. 1988;76(2):159-165.
15. Muss HB, Thor A, Berry DA, et al. c-erbB-2 expression predicts response to adjuvant therapy in women with node positive early breast cancer. New Engl J Med. 1994;330(18):1260-1266.
16. Berry DA, Thor A, Cirrincione C, et al. Scientific inference and predictions; multiplicities and convincing stories: a case study in breast cancer therapy (with discussion). In: Bernardo JM, Berger JO, Dawid AP, Smith AFM, eds. Bayesian Statistics. vol 5. Oxford, UK: Oxford University Press; 1995:45-67.
17. Thor AD, Berry DA, Budman DR, et al. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998;90(18):1346-1360. (Pubitemid 28439959)
18. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998;90(18):1361-1370. (Pubitemid 28439960)
19. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst. 2000;92(24):1991-1998. (Pubitemid 32045895)
20. Ravdin PM, Green S, Albain KS, et al. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF-T with tamoxifen (T) alone. Proc Am Soc Clin Oncol. 1998;17:97a.
21. O'Malley FP, Chai S, Tu D, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst. 2009;101(9):644-650.
22. Pritchard KI, Shepherd LE, O'Malley FP; National Cancer Institute of Canada Clinical Trials Group. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 354(20):2103-11. (Pubitemid 43736610)
23. Baggerly KA, Berry DA. Reproducible research. Amstat News. 2011;403(1):16-17.
24. Begley CG, Ellis LM. Drug development: raise standards for preclinical cancer research. Nature. 2012;483(7391):531-533.
25. Begley S. In cancer science, many 'discoveries' don't hold up. Mar 28, 2012. http://www.reuters.com/article/2012/03/28/us-science-cancer- idUSBRE82R12P20120328. Accessed July 11, 2012.
26. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97(16):1180-1184. (Pubitemid 41258223)
27. Thompson J. Six Seconds in Dallas. New York, NY: Bernard Geis/Random House Inc; 1968.
28. Morris E. The umbrella man. http://video.nytimes.com/video/2011/11/21/ opinion/100000001183275/the-umbrella-man.html. Accessed July 11, 2011.
29. Updike J. Comment. The New Yorker. December 9, 1967.